FDA Details Time Clock Strategies for PMAs, 510(k)s in Draft Guidance
The FDA last week released updated guidance describing how it intends to comply with submission review timelines set during user fee negotiations earlier this year.
The documents — on PMAs and 510(k)s — revise guidances from 2008 and 2004, respectively, to explain how the agency will use the actual-time “review clock” schedule established in the FDA Safety & Innovation Act, as well as how actions submitters take might affect the timeline. The four-year spans correspond to the original Medical Device User Fee Authorization Act (MDUFA) and its two reauthorizations.
This summer’s MDUFA III was the first to set some goals in total calendar days, as opposed to “FDA days” that don’t include time the agency spends waiting for responses from devicemakers.
MDUFA III sets a goal for the FDA to have “substantial interaction,” such as a meeting, with PMA filers within 90 FDA days of receipt of 65 percent of applications in 2013. That goal increases to 95 percent by 2017. The total time to decision goal is 395 days for 90 percent of PMAs in 2013, rising to 95 percent in 385 days by 2017.
And that may not be the only upcoming review change for devices.
A California congressman recently announced plans to introduce a bill requiring the FDA to establish an Office of Mobile Health to help speed the development and approval of device apps.
The mobile app market is booming, and devicemakers are often the first to get something out. Is that app technically considered a medical device that would be regulated by the FDA … do you know?
Attendees will come away with ideas on how to transform their traditional devices into apps, a better understanding of what needs FDA approval and lessons learned from a firm that already has an FDA-approved app on the market. Register for this Wednesday webinar rebroadcast today.
Come for this valuable opportunity to hear FDA officials discuss regulatory plans and objectives — and ask questions you need answered; learn from device industry experts, consultants and other experts with actionable tips and strategies you can take straight back to the office; and network with other professionals who understand your challenges; share war stories and insights over a drink. Register Today.Read More
The FDA's new enforcement plan makes one thing clear: Developing a successful CAPA program has never been more important. But creating an FDA-proof CAPA isn’t easy. If only you could pick the brain of someone who is coping successfully with CAPA — the best and the brightest, an industry leader who has devised programs, procedures and solutions that have put companies out in front with the FDA. Well, you can. Register today.Read More
The FDA’s cadre of freshly trained inspectors — many of whom come directly from industry — and increased focus on specialized inspections are making it harder than ever to predict the outcome of your next FDA inspection. Unless, of course, you have Surviving an FDA Inspection at your fingertips. If you could spend less than $400 to get your drug manufacturing facility fully prepared to face a tough inspection by the FDA, would you even hesitate? ... Of course not!